Varicella vaccines
- PMID:22859715
- DOI: 10.1093/bmb/lds019
Varicella vaccines
Abstract
Background: Varicella zoster virus infection (VZV) is widespread and clinically important as the cause of varicella pneumonitis and meningoencephalitis (a complication of primary infection/zoster) and post-herpetic neuralgia (a complication of zoster/secondary infection). The use of live-attenuated varicella vaccine to reduce the burden of these diseases has been established in many countries for a number of years.
Sources of data: Original papers and review articles including guidelines and recommendations by the American Academy of Paediatrics Committee on Infectious Diseases, the Advisory Committee on Immunization Practices and EuroSurveillance.
Areas of agreement: Immunoassay of VZV IgG by enzyme immunosorbent assay is used as a surrogate marker for previous primary infection or successful immunization. Patients who have had natural primary infection do not require vaccination against varicella. Live VZV vaccines are safe and effective at protecting against disease caused by VZV. To ensure long-term protection, a two-dose immunization regime is strongly recommended, due to significant waning of protection following a single dose. Universal two-dose immunization has been shown to be cost-effective in Western temperate countries. In many countries, routine vaccination of children is recommended but, due to cost, often not provided by universal programmes. Cost-effectiveness of a universal programme will be determined by the baseline rate of severe varicella disease.
Areas of controversy: No international consensus exists: measurement of VZV immunity or cost-effectiveness of introducing VZV vaccination to a country. Decisive factors will include the pre-vaccination burden of VZV-associated disease.
Similar articles
- Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.Parment PA, Svahn A, Rudén U, Bråkenhielm G, Storsaeter J, Akesson L, Linde A.Parment PA, et al.Scand J Infect Dis. 2003;35(10):736-42. doi: 10.1080/00365540310015719.Scand J Infect Dis. 2003.PMID:14606613
- Immunogenicity of a two-dose regime of varicella vaccine in children with cancers.Leung TF, Li CK, Hung EC, Chan PK, Mo CW, Wong RP, Chik KW.Leung TF, et al.Eur J Haematol. 2004 May;72(5):353-7. doi: 10.1111/j.1600-0609.2004.00216.x.Eur J Haematol. 2004.PMID:15059071
- Varicella and herpes zoster vaccine development: lessons learned.Warren-Gash C, Forbes H, Breuer J.Warren-Gash C, et al.Expert Rev Vaccines. 2017 Dec;16(12):1191-1201. doi: 10.1080/14760584.2017.1394843. Epub 2017 Oct 30.Expert Rev Vaccines. 2017.PMID:29047317Free PMC article.Review.
- Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).Marin M, Güris D, Chaves SS, Schmid S, Seward JF; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC).Marin M, et al.MMWR Recomm Rep. 2007 Jun 22;56(RR-4):1-40.MMWR Recomm Rep. 2007.PMID:17585291
- Varicella-zoster virus: pathogenesis, incidence patterns and vaccination programs.Gabutti G, Franchi M, Maniscalco L, Stefanati A.Gabutti G, et al.Minerva Pediatr. 2016 Jun;68(3):213-25.Minerva Pediatr. 2016.PMID:27125440Review.
Cited by
- Should varicella vaccine be included in the routine immunization programme?Lin H, Liu Y, Tian L.Lin H, et al.Transl Pediatr. 2014 Oct;3(4):273-4. doi: 10.3978/j.issn.2224-4336.2014.10.01.Transl Pediatr. 2014.PMID:26835345Free PMC article.No abstract available.
- Varicella routine vaccination and the effects on varicella epidemiology - results from the Bavarian Varicella Surveillance Project (BaVariPro), 2006-2011.Streng A, Grote V, Carr D, Hagemann C, Liese JG.Streng A, et al.BMC Infect Dis. 2013 Jul 2;13:303. doi: 10.1186/1471-2334-13-303.BMC Infect Dis. 2013.PMID:23815523Free PMC article.
- Evaluation of a vaccination strategy by serosurveillance data: The case of varicella.Tafuri S, Gallone MS, Gallone MF, Cappelli MG, Chironna M, Germinario C.Tafuri S, et al.Hum Vaccin Immunother. 2015;11(4):897-900. doi: 10.1080/21645515.2015.1009818.Hum Vaccin Immunother. 2015.PMID:25760518Free PMC article.
- Varicella-zoster virus and herpes simplex virus 1 can infect and replicate in the same neurons whether co- or superinfected.Sloutskin A, Yee MB, Kinchington PR, Goldstein RS.Sloutskin A, et al.J Virol. 2014 May;88(9):5079-86. doi: 10.1128/JVI.00252-14. Epub 2014 Feb 26.J Virol. 2014.PMID:24574392Free PMC article.
- The Biology of Varicella-Zoster Virus Replication in the Skin.Tommasi C, Breuer J.Tommasi C, et al.Viruses. 2022 May 6;14(5):982. doi: 10.3390/v14050982.Viruses. 2022.PMID:35632723Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials